Cellectis Stock Price, News & Analysis

Cellectis announced its share and voting rights status as of December 31, 2021. The total number of shares in capital stood at 45,484,810, while the total number of voting rights reached 51,085,782. The company specializes in gene editing and is known for its innovative CAR-T immunotherapies aimed at treating various cancers, including acute myeloid leukemia and multiple myeloma. Cellectis operates from its headquarters in Paris and has a presence in New York and North Carolina. Its commitment to developing life-saving therapies positions it as a leader in the biotech sector.

Cellectis (Nasdaq: CLLS) reported that the FDA has lifted the clinical hold on its partner Allogene Therapeutics’ clinical trials, enabling the resumption of studies for ALLO-501A, an anti-CD19 CAR-T cell therapy. This decision follows investigations revealing that a chromosomal abnormality found in a single patient was unrelated to TALEN® gene editing or Allogene’s manufacturing process. The abnormality's clinical significance was deemed negligible.

Allogene plans to start a pivotal Phase 2 trial for ALLO-501A in relapsed/refractory large B-cell lymphoma by mid-2022.

Cellectis (Nasdaq: CLLS) announced its 2022 business objectives, focusing on ongoing clinical trials BALLI-01, AMELI-01, and MELANI-01. The company aims to enroll patients in these trials and file an IND for UCART20x22, its first dual allogeneic CAR-T product. Cellectis has operational manufacturing sites in Raleigh and Paris, projecting its cash runway into early 2024 with $201 million available as of September 30, 2021. The company is committed to advancing its pipeline of life-saving cell and gene therapies.

Cellectis announced preliminary results from the BALLI-01 Phase 1 study of UCART22, targeting relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study demonstrated that UCART22 can be administered safely after lymphodepletion with FCA, showing no dose-limiting toxicities. Encouraging anti-leukemic activity was observed in 2 out of 6 patients, with one achieving blast reduction to 0%. The trial is currently enrolling at dose level 3. Additionally, preclinical data for TALGlobin01 showed efficient correction of the mutated beta-globulin gene for sickle cell disease.

Cellectis, a gene editing company, reported its share and voting rights on November 30, 2021, with a total of 45,477,810 shares and 51,079,282 voting rights. The company focuses on CAR-T immunotherapies and gene editing technologies for cancer treatment. Headquartered in Paris, Cellectis is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS). The firm targets various cancers, utilizing its TALEN® technology and the PulseAgile system, aiming to address unmet medical needs. For more details, visit www.cellectis.com.

Cytovia Therapeutics has expanded its collaboration with Cellectis to develop gene-edited NK and CAR-NK cells, enhancing cancer treatment options. The agreement includes $20 million in equity for Cytovia and up to $805 million in potential milestones. This strategic partnership also grants Cytovia exclusive rights to modify NK cells using TALEN® technology, facilitating advancement in various cancer indications, particularly in China through their joint venture, CytoLynx Therapeutics. The collaboration aims to leverage innovative immunotherapies targeting unmet medical needs.

Cellectis S.A. (NASDAQ: CLLS) announced significant preclinical data for UCARTMESO, its allogeneic CAR-T cell product candidate targeting mesothelin for the treatment of solid tumors. The data presented at SITC's 36th Annual Meeting indicate that mesothelin is a promising target for CAR-T therapy due to its high expression in certain cancers. UCARTMESO demonstrated potent activity in vitro and in mouse models of pancreatic and pleural mesothelioma. The knockout of TGFBR2 genes enhances its effectiveness even in immunosuppressive tumor environments, suggesting a potential breakthrough in solid tumor treatment.

Cellectis announced its share and voting rights update as of October 31, 2021. The total number of shares in circulation is 45,475,310, while the total number of voting rights stands at 51,076,779. As a gene editing company, Cellectis focuses on CAR-T therapies for oncology and has 21 years of expertise in the field. Its approach includes off-the-shelf gene-edited CAR T-cells and a new platform targeting hemopoietic stem cells for various diseases. Cellectis is listed on Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).

Cellectis S.A. reported a cash position of $216 million as of September 30, 2021, down from $274 million at year-end 2020. The company generated $11 million in revenues for Q3 2021, reflecting an increase from $9 million in Q3 2020, but a decrease to $53 million for the first nine months of 2021 compared to $67 million in the same period of 2020. R&D expenses rose to $34 million in Q3 2021, up from $20 million in Q3 2020. The net loss attributable to shareholders was $37 million for Q3 2021, compared to $30 million in Q3 2020. Preliminary clinical data will be presented at ASH 2021.